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Charcot-Marie-Tooth 1A (CMT1A) is the most common inherited neuropathy without a known therapy, which is 
caused by a 1.4 Mb duplication on human chromosome 17, which includes the gene encoding the peripheral 
myelin protein of 22 kDa (PMP22). Overexpressed PMP22 protein from its gene duplication is thought to cause 
demyelination and subsequently axonal degeneration in the peripheral nervous system (PNS). Here, we 
targeted regulatory region of human PMP22 to normalize overexpressed PMP22 level in C22 mice, a mouse 
model of CMT1A harboring multi copies of human PMP22. Direct local intraneural delivery of CRISPR/Cas9 
designed to target TATA-box of PMP22 before the onset of disease, downregulates gene expression of PMP22 
and preserves both myelin and axons. Notably, the same approach was effective in partial rescue of 
demyelination even after the onset of disease. Collectively, our data present a potential therapeutic efficacy of 





 Figure 1 – Schematic diagram describing  gene editing strategy for CMT1A 
